Dr. Artero graduated in Biochemistry from the Faculty of Biology at the University of Valencia in 1990 and obtained his doctorate with cum laude honors five years later from the same university. After working in a postdoctoral position at the Memorial Sloan-Kettering Cancer Centre in New York for 6 years, where he investigated the molecular basis of myogenic differentiation in Drosophila, he returned to Spain in 2002. He was awarded a contract from the Ramón y Cajal Program and became an Associate Professor in the Genetics Department of the University of Valencia in 2009, where he is currently the secretary and leads the Translational Genomics Laboratory.
His research covers the physiopathological mechanisms of myotonic dystrophy and the discovery of drugs in Drosophila disease models; he is a national pioneer in the application of this technology and derived one of the University of Valencia’s first biotechnological spin-off companies (Valentia BioPharma) from it. His research interests also include the development of treatments for spinal muscular atrophy and the discovery of HER2 receptor heterodimerization inhibitors in breast cancer. He has participated in 33 scientific publications, is an academic editor of the PLOS ONE journal, and is a regular contributor to other prestigious international journals. He is part of the Prometheus Program excellence group and the Valencia regional government’s Collaborative Institute of Biotechnology and Biomedicine (ISIC BIOTECMED; Instituto Superior de Investigación Cooperativa de Biotecnología y Biomedicina) project.
In his innovative capacity, he is the inventor on 7 patents, co-founder of the Genera Biotech company, and a member of the Spanish Association of Scientific and Technical Entrepreneurs.
To strengthen research in the field of miRNAs, in particular in muscular dystrophy. The group published an article in Human Molecular Genetics characterizing three miRNAs that are underexpressed in patients with myotonic dystrophy (MD). Their work aims to identify biomarkers for MD based on serum miRNAs and research focusing on exploring the use of miRNAs as therapeutic targets for MD is already underway.
In a second line of scientific investigation, the group has initiated a European Framework Project with the aim of discovering the molecular basis of heart disturbances in MD by using a Drosophila disease model. They have also obtained encouraging results in new drug-discovery spinal muscular atrophy Drosophila models and continue to collaborate with chemistry groups to develop previously undiscovered drugs for MD.